Regeneron’s Eylea for treating age related macular degeneration gets FDA nod

Regeneron Pharmaceuticals has received marketing approval for their eye drug - Eylea, an injection meant to treat a common cause of blindness in older people. Eylea can be used to treat “wet” age-related macular degeneration. The only other drug approved for the condition is Lucentis from Roche, which was approved in 2006.

The Food and Drug Administration approved Eylea for wet age-related macular degeneration, a leading cause of vision loss in people 60 and older, the company said in a statement today. The drug will hit peak sales of $1.1 billion in 2021 as its use is expanded to other eye disorders, said Yaron Werber, an analyst for Citigroup Inc. in New York. The FDA initially delayed its decision on Aug. 16 saying that answers Regeneron provided to the agency on its application about manufacturing controls were “a major amendment.”

The company spokesperson said Eylea can be injected every eight weeks, half as often as Lucentis. Less frequent dosing may help Eylea capture 16 percent of the U.S. market from Lucentis, Werber said in a telephone interview before the approval was announced. “We think doctors want to experiment with the drug and there’s a lot of interest,” he said. “Cost is very important and we think it’s going to be priced at parity with Lucentis per injection but fewer injections per year.” Werber anticipates Eylea may cost $1,950 an injection. Lucentis is $2,000 for each monthly injection.

Age-related macular degeneration is a breakdown of the eye’s macula, the part of the eye that allows people to see fine detail needed to do tasks such as reading and driving. In the wet form of the disease, there is abnormal growth of blood vessels that can leak fluid into the macula, leading to vision loss. Regeneron estimates about 1.5 million people have the wet form of the disease with 200,000 new cases diagnosed each year.

Dr. Ananya Mandal

Written by

Dr. Ananya Mandal

Dr. Ananya Mandal is a doctor by profession, lecturer by vocation and a medical writer by passion. She specialized in Clinical Pharmacology after her bachelor's (MBBS). For her, health communication is not just writing complicated reviews for professionals but making medical knowledge understandable and available to the general public as well.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Mandal, Ananya. (2020, April 03). Regeneron’s Eylea for treating age related macular degeneration gets FDA nod. News-Medical. Retrieved on November 05, 2024 from https://www.news-medical.net/news/20111121/Regenerons-Eylea-for-treating-age-related-macular-degeneration-gets-FDA-nod.aspx.

  • MLA

    Mandal, Ananya. "Regeneron’s Eylea for treating age related macular degeneration gets FDA nod". News-Medical. 05 November 2024. <https://www.news-medical.net/news/20111121/Regenerons-Eylea-for-treating-age-related-macular-degeneration-gets-FDA-nod.aspx>.

  • Chicago

    Mandal, Ananya. "Regeneron’s Eylea for treating age related macular degeneration gets FDA nod". News-Medical. https://www.news-medical.net/news/20111121/Regenerons-Eylea-for-treating-age-related-macular-degeneration-gets-FDA-nod.aspx. (accessed November 05, 2024).

  • Harvard

    Mandal, Ananya. 2020. Regeneron’s Eylea for treating age related macular degeneration gets FDA nod. News-Medical, viewed 05 November 2024, https://www.news-medical.net/news/20111121/Regenerons-Eylea-for-treating-age-related-macular-degeneration-gets-FDA-nod.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
High levels of microplastics found in prostate tumors, possibly linked to take-out food